Cargando…

225. Dalbavancin Usage in Patients Who Inject Drugs (PWID)

BACKGROUND: Dalbavancin is a lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) secondary to gram-positive organisms. Given its long half-life, there has been increasing off-label use for other indications: osteomyelitis, joint infec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Kaya, Nakagami, Peter, Morita, Kazumi, Gallagher, Jason, Schultz, Sara K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678589/ http://dx.doi.org/10.1093/ofid/ofad500.298

Ejemplares similares

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

2407. Multidisciplinary Endocarditis Team (MET): Establishing a Baseline of Infective Endocarditis in People Who Use Injection Drugs (PWID)
por: Patel, Kaya, et al.
Publicado: (2023)

188. Plan PDD (patient directed discharge): Oral contingency plans for people who inject drugs (PWID) with Staphylococcus aureus bacteremia (SAB) who leave the hospital prematurely
por: Duffield, Olivia, et al.
Publicado: (2023)

1021. Repeat Infective Endocarditis (rIE) in Persons Who Inject Drugs (PWID)
por: Huang, Glen, et al.
Publicado: (2018)

695. Infective endocarditis in people who inject drugs (PWID) at UK Medical Center
por: Cari, Evelyn Villacorta, et al.
Publicado: (2020)

1050. Hepatitis C Infection amongst People who Inject Drugs (PWID): Injection Practices and Risk Factors
por: Sankar, Nityasri, et al.
Publicado: (2020)

1024. First Episode Infective Endocarditis in Persons Who Inject Drugs (PWIDs); A Retrospective Cohort Study
por: Rodger, Laura, et al.
Publicado: (2018)

1409. Infectious Complications in People Who Inject Drugs (PWID): A Retrospective Review and Recommendations for Improved Care
por: Martin, Elena K, et al.
Publicado: (2022)

2266. Microbiology and Predictors of Gram-Negative Infections in Persons Who Inject Drugs with Injection-Related Infections Requiring Hospitalization
por: Mulbah, Jessica L, et al.
Publicado: (2023)

1890. Missed Clinical Opportunities to Prevent Infections and Treat Substance Use Disorder (SUD) in People Who Inject Drugs (PWID)
por: Bardossy, Ana C, et al.
Publicado: (2019)

2897. Collocated Buprenorphine Is Associated with Improved HCV Visit Adherence in People Who Inject Drugs (PWID): Data From the ANCHOR Study
por: Rosenthal, Elana S, et al.
Publicado: (2019)

Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs
por: Lim, Jacqueline, et al.
Publicado: (2022)

1799. Patients Who Inject Drugs (PWID) and Unstable Housing are Associated with Invasive Group A Strep Infection: A retrospective collaboration between two large, quaternary care hospital systems in Philadelphia
por: Loeven, Nicole, et al.
Publicado: (2023)

50. Pilot Study on Offering HIV Pre-Exposure Prophylaxis (PrEP) to People Who Inject Drugs (PWID) in the Inpatient Setting
por: Marryshow, Terry A, et al.
Publicado: (2021)

744. Infectious Diseases Providers Perspectives Around the Use of Outpatient Parenteral Antibiotic Therapy (OPAT) for Persons Who Inject Drugs (PWID), US, 2022
por: Solomon, Daniel A, et al.
Publicado: (2022)

2247. Improvements in Antibiotic Stewardship for Patients Who Use Injection Drugs: Subgroup Analysis of Patients with Bacteremia
por: Duffield, Olivia, et al.
Publicado: (2023)

A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives
por: May, Tom, et al.
Publicado: (2022)

People who inject drugs (PWID) and HIV/aids cases in Mexico City: 1987–2015
por: Romero Mendoza, Martha, et al.
Publicado: (2019)

Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India
por: Solomon, Sunil S., et al.
Publicado: (2016)

Assessing Syringe Exchange Program Access among Persons Who Inject Drugs (PWID) in the District of Columbia
por: Allen, Sean T., et al.
Publicado: (2016)

HIV incidence among people who inject drugs (PWID) in Ukraine: results from a clustered randomized trial
por: Booth, Robert E., et al.
Publicado: (2016)

Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research
por: Abadie, Roberto, et al.
Publicado: (2018)

964. Real-world dalbavancin use for serious gram-positive bacterial infections: comparing outcomes between people who use and do not use drugs
por: Zambrano, Sarah, et al.
Publicado: (2023)

Stigmatization of people who inject drugs (PWID) by pharmacists in Tajikistan: sociocultural context and implications for a pharmacy-based prevention approach
por: Ibragimov, Umedjon, et al.
Publicado: (2017)

Modeling HIV transmission among persons who inject drugs (PWID) at the “End of the HIV Epidemic” and during the COVID-19 pandemic
por: Jarlais, Don Des, et al.
Publicado: (2022)

587. HIV Care Outcomes Among PWID in San Francisco, 2009–2015
por: Kim, Nathan, et al.
Publicado: (2018)

Rapid situational assessment of people who inject drugs (PWID) in Nairobi and coastal regions of Kenya: a respondent driven sampling survey
por: Oguya, Francis O., et al.
Publicado: (2021)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

1071. Social Determinants of health (SDOH) among PWID living with HCV
por: Corro, Luis Gonzalez, et al.
Publicado: (2020)

108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Wei, Wenjing, et al.
Publicado: (2021)

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis
por: Rajabi, Abdolhalim, et al.
Publicado: (2021)

A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic
por: Bradley, Heather, et al.
Publicado: (2022)

Oral Pre-Exposure Prophylaxis (PrEP) Awareness and Acceptability Among Persons who Inject Drugs (PWID) in Kenya: A Qualitative Investigation
por: Cosmas, Mugambi, et al.
Publicado: (2023)

Prevalence of HIV, risk behaviours and vulnerabilities of female sex partners of the HIV positive people who inject drugs (PWID) in Dhaka city, Bangladesh
por: Reza, Md. Masud, et al.
Publicado: (2023)

Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions
por: Sazonova, Yana, et al.
Publicado: (2023)

The Effects of live- in rehabilitation on ARV adherence, abstinence from drugs and lifestyle modification in people who inject drugs (PWID) Living with HIV – A clinic review
por: Hussain, Aneela, et al.
Publicado: (2022)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS‐FANTASIO study)
por: Barré, Tangui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_619m1hetj9gbir1o3nksg5mvb7